The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: RESULTS from the Community-Acquired Pneumonia Organization (CAPO) international cohort study

Vaccine

Volumn 32, Issue 19, 2014, Pages 2198-2203

  Wiemken, Timothy L ^a   Carrico, Ruth M ^a   Klein, Sabra L ^b   Jonsson, Colleen B ^a   Peyrani, Paula ^a   Kelley, Robert R ^a   Aliberti, Stefano ^c   Blasi, Francesco ^d   Fernandez Gonzalez, Ricardo ^e   Lopardo, Gustavo ^f   Ramirez, Julio A ^a  

^a University of Louisville School of Medicine   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e San Juan City Hospital   (Puerto Rico)

^f Dipartimento di Fisiopatologia e dei Trapianti University of Milan IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico ^*  (Argentina)

Author keywords

Immunology; Pneumococcus; Sex differences; Vaccine effectiveness; Vaccinology

Indexed keywords

PNEUMOCOCCUS VACCINE;

AGED; ARTICLE; BACTERIUM IDENTIFICATION; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HOSPITALIZATION; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; NONHUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

IMMUNOLOGY; PNEUMOCOCCUS; SEX DIFFERENCES; VACCINE EFFECTIVENESS; VACCINOLOGY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; ODDS RATIO; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; SEX FACTORS;

EID: 84897110556     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.02.048     Document Type: Article

References (21)

1. World Health Organization The top 10 causes of death. Geneva 2010, Available from: http://www.who.int/mediacentre/factsheets/fs310/en/index.html.
2. Cilloniz C., Polverino E., Ewig S., Aliberti S., Gabarrus A., Menendez R., et al. Impact of age and comorbidity on etiology and outcome in community-acquired pneumonia. Chest 2013, 144(3):999-1007.
3. Jackson L.A., Janoff E.N. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis 2008, 47(10):1328-1338.
4. Centers for Disease Control and Prevention Adult vaccination coverage - United States, 2010. MMWR Morb Mortal Wkly Rep 2012, 61(4):66-72.
5. Centers for Disease Control and Prevention Influenza and pneumococcal vaccination coverage among persons aged >65 years - United States, 2004-2005. MMWR Morb Mortal Wkly Rep 2006, 55(39):1065-1068.
6. Pitsiou G.G., Kioumis I.P. Pneumococcal vaccination in adults: does it really work?. Respir Med 2011, 105(12):1776-1783.
7. Mykietiuk A., Carratala J., Dominguez A., Manzur A., Fernandez-Sabe N., Dorca J., et al. Effect of prior pneumococcal vaccination on clinical outcome of hospitalized adults with community-acquired pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 2006, 25(7):457-462.
8. Fisman D.N., Abrutyn E., Spaude K.A., Kim A., Kirchner C., Daley J. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis 2006, 42(8):1093-1101.
9. Klein S.L., Jedlicka A., Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis 2010, 10(5):338-349.
10. Cook I.F. Sexual dimorphism of humoral immunity with human vaccines. Vaccine 2008, 26(29-30):3551-3555.
11. Klein S.L., Poland G.A. Personalized vaccinology: one size and dose might not fit both sexes. Vaccine 2013, 31(23):2599-2600.
12. Ramirez J.A. Fostering international multicenter collaborative research: the CAPO Project. Int J Tuberc Lung Dis 2007, 11(10):1062-1065.
13. Valenciano M., Kissling E., Ciancio B.C., Moren A. Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks. Vaccine 2010, 28(46):7381-7388.
14. R Core Team R: a language and environment for statistical computing 2012, R Foundation for Statistical Computing, Vienna, Austria, Available from: http://www.R-project.org.
15. Harrell F. Regression modeling strategies. 4.0-0 ed2013.
16. Lumley T. Survey: analysis of complex survey samples. 3.28-2 ed2013.
17. Cook I.F. Sex differences in injection site reactions with human vaccines. Hum Vaccines 2009, 5(7):441-449.
18. Magnusson S.E., Reimer J.M., Karlsson K.H., Lilja L., Bengtsson K.L., Stertman L. Immune enhancing properties of the novel Matrix-M adjuvant leads to potentiated immune responses to an influenza vaccine in mice. Vaccine 2013, 31(13):1725-1733.
19. Umlauf B.J., Haralambieva I.H., Ovsyannikova I.G., Kennedy R.B., Pankratz V.S., Jacobson R.M., et al. Associations between demographic variables and multiple measles-specific innate and cell-mediated immune responses after measles vaccination. Viral Immunol 2012, 25(1):29-36.
20. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., et al. Glycoprotein-d-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002, 347(21):1652-1661.
21. Jackson M.L., Nelson J.C. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 2013, 31(17):2165-2168.